comparemela.com

Latest Breaking News On - Ad hd - Page 1 : comparemela.com

Meth is posing as popular prescription drug, DEA warns

A dangerous and addictive drug has now infiltrated Massachusetts communities. Disguised as Adderall, the popular stimulant used to treat ADHD, methamphetamine is now popping up across Massachusetts in pressed pill form.

Automatic sensory change processing in adults with attention deficit a by Chen Dang, Xiangsheng Luo et al

In addition to higher-order executive functions, underlying sensory processing ability is also thought to play an important role in Attention-Deficit/Hyperactivity Disorder (AD/HD). An event-related potential feature, the mismatch negativity, reflects the ability of automatic sensory change processing and may be correlated with AD/HD symptoms and executive functions. This study aims to investigate the characteristics of visual mismatch negativity (vMMN) in adults with AD/HD. Twenty eight adults with AD/HD and 31 healthy controls were included in this study. These two groups were matched in age, IQ and sex. In addition, both groups completed psychiatric evaluations, a visual ERP task used to elicit vMMN, and psychological measures about AD/HD symptoms and day-to-day executive functions. Compared to trols, the late vMMN (230–330 ms) was significantly reduced in the AD/HD group. Correlation analyses showed that late vMMN was correlated with executive functions but not AD/HD symptoms. Ho

ADHD s possible link to 7 common mental disorders

Researchers now say ADHD may increase the risk for depression, anorexia even suicide. Dr. Alice Connors-Kellgren, a clinical psychologist at Tufts Medical Center, answers questions.

Remote neurocognitive interventions for attention-deficit/hyperactivit by Da Wei Zhang, Stuart J Johnstone et al

Improving neurocognitive functions through remote interventions has been a promising approach to developing new treatments for attention-deficit/hyperactivity disorder (AD/HD). Remote neurocognitive interventions may address the shortcomings of the current prevailing pharmacological therapies for AD/HD, e.g., side effects and access barriers. Here we review the current options for remote neurocognitive interventions to reduce AD/HD symptoms, including cognitive training, EEG neurofeedback training, transcranial electrical stimulation, and external cranial nerve stimulation. We begin with an overview of the neurocognitive deficits in AD/HD to identify the targets for developing interventions. The role of neuroplasticity in each intervention is then highlighted due to its essential role in facilitating neuropsychological adaptations. Following this, each intervention type is discussed in terms of the critical details of the intervention protocols, the role of neuroplasticity, and the ava

Mass doctor on Adderall shortage

The FDA says the shortage is expected to last another 30 to 60 days. It’s happening in part due to surging demand for Adderall and manufacturing delays.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.